Skip to main content

Enter your keywords

Why Us?
Our Services
Research Team
Therapeutic Experience
Publications
Careers
Contact

Updates and Events
Resources

Breadcrumb

Home
Publications
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors For Tardive Dyskinesia: Effectiveness and Value

Walton SM, Harrigan (Zhang) K, Touchette DR. Vesicular monoamine transporter 2 (VMAT2) inhibitors for tardive dyskinesia: effectiveness and value. 2017.

Abstract not available at this time.

Share on:

Why Us?

Steeped in a tradition of rigor and process, we maintain a legacy of setting scientific standards within our industry. We employ the right approaches and proven research practices to analyze evidence and draw meaningful insights. Our uncompromisingly ethical and objective researchers ensure that results will hold up to scrutiny and reveal the benefits, risks, value, and potential of your products. Learn more.

Quick Links

Our Services
Therapeutic Experience
Publications
Resources
Updates and Events

More About RTI-HS

About Us
Research Team
Careers
Data Protection

Connect

To learn more about our research and consulting services, please call us at:

US: +1.800.262.3011
Spain: +34.93.241.7766
UK: +44(0)161.447.6000
Contact us

© 2023 RTI Health Solutions. Website Privacy Policy | Cookie Policy | Data Protection | Research Privacy Policy

Contact our webmaster

California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices | Notice at Collection